Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Carfilzomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 17/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 3/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 3/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 3/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 3/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 1/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
| ▸ | PSMD12 known ✓ | O00232 | 1/20 | 1.00 |
| ▸ | PSMD14 known ✓ | O00487 | 1/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 1/20 | 1.00 |
| ▸ | PSMD3 known ✓ | O43242 | 1/20 | 1.00 |
| ▸ | PSMC3 known ✓ | P17980 | 1/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 1/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 1/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 1/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 1/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 1/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 1/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 1/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carfilzomib SCHEMBL21036021 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036176 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21035430 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036163 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL23616374 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036204 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL24140134 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21367423 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL25438395 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL20825319 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13895 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4748376-A2 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF T CELL REDIRECTING THERAPEUTICS | Janssen Biotech, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636340-B2 | Methods of treating multiple myeloma | ONYX PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103292-A1 | ZOMIB-BASED NANOMICELLAR FORMULATION AND PREPARATION METHOD THEREFOR | 江苏百奥信康医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137776-A1 | COMBINATION THERAPY OF A GPRC5D TCB AND PROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4743119-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-11241502-B2 | Stable compositions of pegylated carfilzomib compounds | AMGEN INC. (US) | 2022-02-08 | — | — | US | claimed |
| CN-114026121-A | Methods of treating multiple myeloma | 赛诺菲 | 2022-02-08 | — | — | CN | claimed |
| WO-2022022599-A1 | METHOD FOR AMPLIFYING IN-VITRO INDUCED CD4 +FOXP3 +CD69 +TREG AND USE THEREOF | 浙江大学 | 2022-02-03 | — | — | WO | claimed |
| US-20220031840-A1 | Method of Treatment | HAEMALOGIX PTY LTD (AU) | 2022-02-03 | — | — | US | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3941919-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES | Genentech, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | claimed |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |